| Literature DB >> 33145056 |
Huan Liu1, Shun Liu1, Anthony Zaki2, Xiuwen Wang1, Kai Zhu3, Yuntao Lu1, Ye Yang1, Rafi Hamidi1, Lai Wei1, Chunsheng Wang1.
Abstract
BACKGROUND: Adults with unrepaired tetralogy of Fallot (ToF) are common in developing countries. Long-term overload of the right ventricle places adult patients at risk for postoperative right heart failure after primary repair, which contributes to morbidity and mortality. The effect of pulmonary valve replacement (PVR) in reducing postoperative morbidity and mortality in adults has never been validated.Entities:
Keywords: Tetralogy of Fallot (ToF); adult congenital heart disease; pulmonary valve replacement; right heart failure
Year: 2020 PMID: 33145056 PMCID: PMC7578467 DOI: 10.21037/jtd-20-1475
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Demographics and baseline characteristics
| TA-PVR (n=12) | TA (n=29) | AP (n=15) | Total (N=56) | P | |
|---|---|---|---|---|---|
| Female | 2 (16.7)a | 20 (69.0)b | 8 (53.3) | 30 (53.6) | 0.009 |
| Age (years) | 42.2±10.9 | 40.1±12.6 | 43.7±10.9 | 41.5±11.7 | 0.617 |
| Hypertension | 0 | 3 (10.3) | 0 | 3 (5.4) | 0.416 |
| Diabetes | 0 | 0 | 0 | 0 | NA |
| Stroke | 0 | 1 (3.4) | 0 | 1 (1.8) | 1.000 |
| sCr (ìmol/L) | 78.3±19.6 | 69.4±17.0 | 76.2±19.7 | 73.2±18.4 | 0.290 |
| GFR (mL/min) | 96.3±14.5 | 99.6±19.0 | 93.9±23.0 | 97.4±19.2 | 0.644 |
| NT-proBNP (pg/ml) | 320.5 (97.4, 1,091.5) | 217.8 (110.8, 472.6) | 97.5 (54.3, 878.8) | 203.8 (87.6, 675.9) | 0.385 |
sCr, serum creatinine; GFR, glomerular filtration rate. a,b, significant difference between groups.
Baseline echocardiography
| TA-PVR (n=12) | TA (n=29) | AP (n=15) | Total (N=56) | P | |
|---|---|---|---|---|---|
| Size of VSD (mm) | 22.1±6.1 | 20.6±3.8 | 19.6±4.7 | 20.6±4.5 | 0.456 |
| RVOT pressure gradient (mmHg) | 113.8±35.0 | 105.8±27.8 | 95.0±20.6 | 104.6±28.1 | 0.218 |
| Pulmonary valve thickened and immobile | 12 (100.0) | 26 (89.7) a | 11 (73.3) b | 49 (87.5) | 0.041 |
| Thickness of RV (mm) | 10.9±1.5 | 10.3±2.9 | 9.5±2.6 | 10.2±2.6 | 0.501 |
| Diameter of PT (mm) | 23.4±9.3a | 17.7±5.8b | 22.3±7.4 | 20.2±7.4 | 0.036 |
| Diameter of LPA (mm) | 20.0±7.7a | 13.0±4.0b | 15.4±4.6b | 15.2±5.8 | 0.002 |
| Diameter of RPA (mm) | 17.3±7.4 | 13.5±4.1 | 17.5±6.2 | 15.4±5.8 | 0.051 |
| Aortic root (mm) | 38.3±6.3 | 36.6±4.7 | 38.6±5.6 | 37.5±5.3 | 0.409 |
| LVEDD (mm) | 45.0±10.7b | 38.6±7.8a | 45.9±8.0b | 41.9±9.1 | 0.014 |
| LVEF (%) | 64.5±4.8 | 65.8±4.0 | 65.0±6.8 | 65.3±5.0 | 0.742 |
| AR more than mild | 2 (16.7) | 3 (10.3) | 2 (13.3) | 7 (12.5) | 0.871 |
| MR more than mild | 0 | 1(3.4) | 0 | 1 (1.8) | 1.000 |
| TR more than mild | 5 (41.7) | 9 (31.0) | 5 (33.3) | 19 (33.9) | 0.806 |
| PFO/ASD | 3 (25.0) | 3 (10.3) | 2 (13.3) | 8 (14.3) | 0.467 |
ASD, atrial septal defect; AR, aortic regurgitation; LPA, left pulmonary artery; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; PFO, patent foramen ovale; PT, pulmonary trunk; RPA, right pulmonary artery; RV, right ventricle; RVOT, right ventricular outflow track; TR, tricuspid regurgitation; VSD, ventricular septal defect. a,b, significant difference between groups.
Procedural outcomes
| TA-PVR (n=12) | TA (n=29) | AP (n=15) | Total (N=56) | P | |
|---|---|---|---|---|---|
| CPB time (min) | 178.4±36.5a | 135.4±33.0b | 134.3±48.9b | 144.7±42.2 | 0.008 |
| Cross-clamp time (min) | 112.6±28.9a | 80.1±34.6b | 79.4±31.2b | 87.2±34.7 | 0.019 |
| Prothesis size (mm) | |||||
| 25 | 9 (75.0) | NA | NA | NA | NA |
| 23 | 1 (8.3) | NA | NA | NA | NA |
| 21 | 2 (16.7) | NA | NA | NA | NA |
| Concomitant surgery | |||||
| PFO/ASD repair | 4 (33.3) | 8 (27.6) | 5 (33.3) | 17 (30.4) | NA |
| PDA repair | 0 | 2 (6.9) | 1 (6.7) | 3 (5.4) | NA |
| Systemic-to-pulmonary collateral embolization | 1 (8.3) | 0 | 0 | 1 (1.8) | NA |
| Tricuspid repair | 3 (25.0) | 2 (6.9) | 4 (26.7) | 9 (16.1) | NA |
| AVR | 0 | 1 (3.4) | 1 (6.7) | 2 (3.6) | NA |
| CABG | 1 (8.3) | 0 | 0 | 1 (1.8) | NA |
| Subaortic stenosis repair | 0 | 1 (3.4) | 1 (6.7) | 2 (3.6) | NA |
ASD, atrial septal defect; AVR, aortic valve replacement; CABG, coronary artery bypass graft; CPB, cardiopulmonary bypass; PDA, patent ductus arteriosus; PFO, patent foramen ovale. a,b, significant difference between groups.
The postoperative outcomes
| TA-PVR (n=12) | TA (n=29) | AP (n=15) | Total (N=56) | P | |
|---|---|---|---|---|---|
| Operative mortality | 0 | 3 (10.3) | 1 (6.7) | 4 (7.1) | 0.801 |
| Right heart failure | 3 (25.0) | 6 (20.7) | 1 (6.7) | 10 (17.9) | 0.421 |
| AKI | 4 (33.3) | 8 (27.6) | 4 (26.7) | 16 (28.6) | 0.803 |
| Stage 1 | 4 (33.3) | 4 (13.8) | 3 (20.0) | 11 (19.6) | NA |
| Stage 2 | 0 | 2 (6.9) | 0 | 2 (3.6) | NA |
| Stage 3 | 0 | 2 (6.9) | 1 (6.7) | 3 (5.4) | 1.000 |
| RRT | 0 | 2 (6.9) | 1 (6.7) | 3 (5.4) | 1.000 |
| Length of ICU stay (days) | 11.1±14.0 | 6.1±10.9 | 2.7±1.8 | 6.3±10.5 | 0.118 |
| Length of postoperative hospital stay (days) | 16.8±14.2a | 11.9±9.8 | 7.1±2.2b | 11.6±10.1 | 0.043 |
| MV time (hours) | 160.0±273.9 | 105.7±273.7 | 23.5±27.4 | 95.3±236.0 | 0.315 |
| Prolonged ventilation | 4 (33.3) a | 3 (10.3) | 0b | 7 (12.5) | 0.038 |
| Chest tube output in first postoperative 24 hours (mL) | 490.8±306.7 | 496.6±551.8 | 313.3±198.0 | 446.3±436.3 | 0.393 |
| RBC (Units) | 0.8±1.3 | 1.9±4.2 | 1.8±3.1 | 1.6±3.4 | 0.659 |
| Pericardial effusion | 4 (33.3) | 6 (20.7) | 3 (20.0) | 13 (23.2) | 0.699 |
| Pleural effusion | 12 (100.0) | 25 (86.2) | 12 (80.0) | 49 (87.5) | 0.324 |
AKI, acute kidney injury; MV, mechanical ventilation; RRT, renal replacement therapy. a,b, significant difference between groups.